Biotinylated Human IL-23 alpha&IL-12 beta Heterodimer Protein, His,Avitag?&Tag Free (MALS verified)
分子別名（Synonym）
IL-23 alpha & IL-12 beta
表達(dá)區(qū)間及表達(dá)系統(tǒng)（Source）
Biotinylated Human IL-23 alpha&IL-12 beta Heterodimer Protein, His,Avitag&Tag Free (ILB-H82W6) is expressed from human 293 cells (HEK293). It contains AA Arg 20 - Pro 189 (IL23A) & Ile 23 - Ser 328 (IL12B) (Accession # Q9NPF7-1 (IL23A) & P29460-1 (IL12B)).
Predicted N-terminus: His (IL23A) & Ile 23 (IL12B)
蛋白結(jié)構(gòu)（Molecular Characterization）
Biotinylated Human IL-23A&IL-12B Heterodimer Protein, His,Avitag&Tag Free, produced by co-expression of IL23A and IL12B, has a calculated MW of 21.9 kDa (IL23A) & 34.7 kDa (IL12B). Subunit IL23A is fused with an Avi tag (Avitag?), followed by a polyhistidine tag at the N-terminus and subunit IL12B contains no tag. The protein migrates as 23-25 kDa (IL23A) & 37-39 kDa (IL12B) when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.
標(biāo)記（Labeling）
Biotinylation of this product is performed using Avitag? technology. Briefly, the single lysine residue in the Avitag is enzymatically labeled with biotin.
蛋白標(biāo)記度（Protein Ratio）
Passed as determined by the HABA assay / binding ELISA.
純度（Purity）
>95% as determined by SDS-PAGE.
制劑（Formulation）
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
重構(gòu)方法（Reconstitution）
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
存儲(chǔ)（Storage）
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.
背景介紹
白細(xì)胞介素-23 α亞基（IL-23 alpha）可與IL12B結(jié)合形成IL-23白細(xì)胞介素，這是一種在先天性和適應(yīng)性免疫中發(fā)揮作用的異二聚體細(xì)胞因子。在外周組織中，IL-23可能與IL-17共同構(gòu)成對(duì)感染的急性反應(yīng)機(jī)制。IL-23通過與IL12RB1和IL23R組成的異二聚體受體復(fù)合物結(jié)合，激活Jak-Stat信號(hào)級(jí)聯(lián)反應(yīng)，特異性刺激記憶T細(xì)胞（而非初始T細(xì)胞），并促進(jìn)促炎細(xì)胞因子的產(chǎn)生。該細(xì)胞因子可引發(fā)自身免疫性炎癥，因此可能是自身免疫性炎癥疾病的致病因子，并可能參與腫瘤發(fā)生過程。
關(guān)鍵字： IL23A & IL12B;IL23A蛋白;IL12B重組蛋白;ACRO;百普賽斯;
百普賽斯集團(tuán)ACROBiosystems Group（股票代碼：301080）是成立于2010年的跨國生物科技公司，是為全球生物醫(yī)藥、健康產(chǎn)業(yè)領(lǐng)域提供關(guān)鍵生物試劑產(chǎn)品及解決方案的行業(yè)平臺(tái)型基石企業(yè)。2021年在創(chuàng)業(yè)板上市。百普賽斯集團(tuán)業(yè)務(wù)遍布全球，橫跨亞洲、北美洲、歐洲，在中國、美國、瑞士等12個(gè)城市設(shè)有辦公室、研發(fā)中心及生產(chǎn)基地。目前累計(jì)服務(wù)客戶超6000家，與全球Top 20醫(yī)藥企業(yè)均建立了長期、穩(wěn)定的合作伙伴關(guān)系。集團(tuán)旗下?lián)碛衅放艫CROBiosystems百普賽斯、bioSeedin柏思薈、Condense Capital墾拓資本和ACRODiagnostics百斯醫(yī)學(xué)等。